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Cancer stem cells represent a small number of pluripotent 
and self-renewing cells within a tumor, which are resistant to 
conventional chemotherapy and are responsible for tumor 
initiation  and  maintenance.  The  Wnt/β-catenin  signaling 
pathway drives stem cell self-renewal and is involved in the 
pathogenesis of various types of cancer. Aberrant activation of 
the Wnt signaling pathway in normal stem cells can promote their 
transformation into cancer stem cells [1,2]. Thus, drugs targeted 
to the Wnt/β-catenin pathway may potentially be effective in 
eliminating cancer stem cells. Recently, several small molecule 
Wnt  signaling  inhibitors  have  been  identified,  that  can  have 
therapeutic potential against cancers associated with aberrant 
Wnt signaling [3]. However, most reported Wnt inhibitors are 
still in the developmental stage, due to lack of specificity and 
a poor understanding of their precise mechanisms of action. 
Furthermore, there is limited evidence that these Wnt signaling 
inhibitors can eradicate cancer stem cells, without depleting 
normal stem cells in the bone marrow and the gastrointestinal 
tract.
Salinomycin, an antibiotic potassium ionophore, is the 
first drug reported to act as a selective breast cancer stem cell 
inhibitor. It kills breast cancer stem cells at least 100 times more 
effectively than paclitaxel in mice, but is relatively non-toxic 
to normal stem cells [4]. The mechanism of salinomycin action 
in the cancer stem cells remains unclear. Our recent studies 
have shown that salinomycin potently inhibits proximal Wnt/
β-catenin signaling. It blocks the phosphorylation of the Wnt 
co-receptor LRP6, and induces its degradation [5]. Considering 
the importance of Wnt signaling in stem cell biology, the 
Wnt antagonistic action of salinomycin may contribute to its 
selective toxicity toward breast cancer stem cells. It will be 
interesting to test whether other Wnt signaling inhibitors with 
targets downstream of LRP6 are able to kill selectively breast 
cancer stem cells.
A successful anticancer therapeutic regime should 
eliminate both the differentiated cancer cells and the cancer 
stem cell population. Classical cytotoxic agents may deplete 
the bulk of a cancer but not the inherently chemo-resistant 
cancer stem cells, which ultimately recur and metastasize. The 
molecularly targeted agents act on aberrant molecular pathways 
associated with tumor development and progression, and have 
been successfully introduced to treat patients with various 
cancers [6]. These drugs include Bcr-abl inhibitors, epidermal 
growth factor receptor (EGFR) inhibitors, vascular endothelial 
growth factor (VEGF) antagonists, and recently Raf kinase 
and Alk kinase inhibitors. These single-target agents have 
spectacularly initial clinical efficacy when used alone, but none 
are able to cure a cancer. Future experiments need to determine 
if the combination of a single-target agent with salinomycin or 
other Wnt signaling inhibitors might have the ability to induce 
curative response in some tumors. 
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